CymaBay Therapeutics (CBAY) Gets a Buy Rating from Evercore ISI

By Jason Carr

In a report issued on November 22, Joshua Schimmer from Evercore ISI maintained a Buy rating on CymaBay Therapeutics (CBAYResearch Report), with a price target of $12.00. The company’s shares closed last Monday at $5.55, close to its 52-week low of $4.23.

According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 10.2% and a 50.7% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Alexion Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CymaBay Therapeutics with a $13.80 average price target.

See today’s analyst top recommended stocks >>

Based on CymaBay Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $26.28 million. In comparison, last year the company had a GAAP net loss of $18.56 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.